NASDAQ
RXDX

Prometheus Biosciences Inc

Biotechnology & Medical Research
Healthcare

Prices are adjusted according to historical splits.

Prometheus Biosciences Inc Stock Price

Vitals

Today's Low:
$199.6
Today's High:
$199.98
Open Price:
$199.68
52W Low:
$30.75
52W High:
$199.98
Prev. Close:
$199.74
Volume:
1860653

Company Statistics

Market Cap.:
$9.56 billion
Book Value:
14.621
Revenue TTM:
$4.00 million
Operating Margin TTM:
-4064.73%
Gross Profit TTM:
$-106039000
Profit Margin:
0%
Return on Assets TTM:
-20.06%
Return on Equity TTM:
-33.3%

Company Profile

Prometheus Biosciences Inc had its IPO on 2021-03-12 under the ticker symbol RXDX.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Prometheus Biosciences Inc has a staff strength of 97 employees.

Stock update

Shares of Prometheus Biosciences Inc opened at $199.68 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $199.6 - $199.98, and closed at $199.92.

This is a +0.09% increase from the previous day's closing price.

A total volume of 1,860,653 shares were traded at the close of the day’s session.

In the last one week, shares of Prometheus Biosciences Inc have increased by +0.54%.

Prometheus Biosciences Inc's Key Ratios

Prometheus Biosciences Inc has a market cap of $9.56 billion, indicating a price to book ratio of 19.8767 and a price to sales ratio of 627.821.

In the last 12-months Prometheus Biosciences Inc’s revenue was $4.00 million with a gross profit of $-106039000 and an EBITDA of $-161611008. The EBITDA ratio measures Prometheus Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Prometheus Biosciences Inc’s operating margin was -4064.73% while its return on assets stood at -20.06% with a return of equity of -33.3%.

In Q1, Prometheus Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 71.8%.

Prometheus Biosciences Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-3.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Prometheus Biosciences Inc’s profitability.

Prometheus Biosciences Inc stock is trading at a EV to sales ratio of 610.455 and a EV to EBITDA ratio of -33.1637. Its price to sales ratio in the trailing 12-months stood at 627.821.

Prometheus Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$758.41 million
Total Liabilities
$19.34 million
Operating Cash Flow
$-192333000.00
Capital Expenditure
$530000
Dividend Payout Ratio
0%

Prometheus Biosciences Inc ended 2024 with $758.41 million in total assets and $0 in total liabilities. Its intangible assets were valued at $758.41 million while shareholder equity stood at $697.62 million.

Prometheus Biosciences Inc ended 2024 with $15.48 million in deferred long-term liabilities, $19.34 million in other current liabilities, 5000.00 in common stock, $-371969000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $113.35 million and cash and short-term investments were $713.67 million. The company’s total short-term debt was $3,485,000 while long-term debt stood at $0.

Prometheus Biosciences Inc’s total current assets stands at $726.40 million while long-term investments were $0 and short-term investments were $600.33 million. Its net receivables were $0.00 compared to accounts payable of $1.16 million and inventory worth $0.

In 2024, Prometheus Biosciences Inc's operating cash flow was $-192333000.00 while its capital expenditure stood at $530000.

Comparatively, Prometheus Biosciences Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$199.92
52-Week High
$199.98
52-Week Low
$30.75
Analyst Target Price
$195

Prometheus Biosciences Inc stock is currently trading at $199.92 per share. It touched a 52-week high of $199.98 and a 52-week low of $199.98. Analysts tracking the stock have a 12-month average target price of $195.

Its 50-day moving average was $184.19 and 200-day moving average was $109.6 The short ratio stood at 3.97 indicating a short percent outstanding of 0%.

Around 1660.9% of the company’s stock are held by insiders while 8101.4% are held by institutions.

Frequently Asked Questions About Prometheus Biosciences Inc

The stock symbol (also called stock or share ticker) of Prometheus Biosciences Inc is RXDX

The IPO of Prometheus Biosciences Inc took place on 2021-03-12

Similar Industry Stocks (Biotechnology & Medical Research)

Last Price
Chg
Chg%
$0.6
0.04
+7.14%
Ocugen Inc (OCGN)
$0.42
0
0%
$10.65
0
0%
$1037.7
-29.45
-2.76%
$132.2
-11.35
-7.91%
$5.39
0
0%
$545.2
-5
-0.91%
$0.04
0
0%
$29.11
0.38
+1.32%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

Address

9410 Carroll Park Drive, San Diego, CA, United States, 92121